What's in Zheng Liu ENT's pipeline?

Zheng Liu ENT has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Zheng Liu ENT's portfolio?

Top competitors by shared drug class: Association Asthma, Bulgaria, AstraZeneca, Beijing Tongren Hospital, Children's Hospital of Philadelphia, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zheng-liu-ent.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Zheng Liu ENT — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zheng Liu ENT pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Mometasone furoate as a nasal spray	Mometasone furoate as a nasal spray	phase 3	Intranasal corticosteroid	Glucocorticoid receptor	Otolaryngology / Allergy

Therapeutic area mix

Otolaryngology / Allergy · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Association Asthma, Bulgaria · 1 shared drug class
AstraZeneca · 1 shared drug class
Beijing Tongren Hospital · 1 shared drug class
Children's Hospital of Philadelphia · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Glenmark Specialty S.A. · 1 shared drug class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 shared drug class
National University of Malaysia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zheng Liu ENT:

Cite this brief

Drug Landscape (2026). Zheng Liu ENT — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zheng-liu-ent. Accessed 2026-05-17.